Inhibition of PCSK9 is a new therapeutic strategy for the control of hyperlipidemia, which can improve LDL-R circulation, increase the utilization of LDL-R on the surface of liver cells, and reduce the level of LDL-C in the blood. This evidence concerns the gene PCSK9 and hyperlipidemia.